Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis

Keyphrases

• Individual Patient Data Meta-analysis 100%
• Falciparum Malaria 100%
• Primaquine 100%
• Daily Dose 42%
• Total Dose 38%
• Plasmodium Vivax 15%
• Adjusted Hazard Ratio 11%
• Serious Adverse Events 11%
• Gastrointestinal Diseases 11%
• Parasitemia 11%
• Children Younger than 5 Years 11%
• Recurrence Rate 7%
• Ultra-low Dose 7%
• High Glucose 7%
• Glucose-6-phosphate Dehydrogenase Activity 7%
• Health Research 3%
• Diarrhea 3%
• Vomiting 3%
• Treatment Group 3%
• Between-day 3%
• Tolerability 3%
• Hemoglobin 3%
• Drug Dependence 3%
• Efficacy Study 3%
• Cumulative Incidence 3%
• Risk-adjusted 3%
• Prospero 3%
• Medical Research Council 3%
• National Health 3%
• Missing Data 3%
• Bill & Melinda Gates Foundation 3%
• Individual Patient Data 3%
• Time-to-event Analysis 3%
• Anorexia 3%
• Adjusted Dose 3%
• Dosing Regimen 3%
• Protocol Compliance 3%
• Medicines for Malaria Venture 3%
• Severe Malaria 3%
• Hemoglobin Decrease 3%
• Relative Rate 3%
• Absolute Change 3%
• Pediatric Formulations 3%

Pharmacology, Toxicology and Pharmaceutical Science

• Plasmodium Vivax Malaria 100%
• Primaquine 100%
• Adverse Event 11%
• Recurrent Disease 11%
• Parasitemia 11%
• Gastrointestinal Symptom 11%
• Glucose 6 Phosphate Dehydrogenase 7%
• Diarrhea 3%
• Tablet 3%
• Tolerability 3%
• Efficacy Study 3%
• Antimalarial Agent 3%
• Anorexia 3%
• Treatment Group 3%